Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis.

Authors:
Ellen Deschepper
Ellen Deschepper
Ghent University Hospital
Belgium
Kurt Audenaert
Kurt Audenaert
Ghent University Hospital
Eric Constant
Eric Constant
Université Catholique de Louvain
Belgium
Michel Floris
Michel Floris
General Hospital Sint-Jan Brugge-Oostende AV
Belgium
William Pitchot
William Pitchot
University of Liège
Belgium
Pascal Sienaert
Pascal Sienaert
University Psychiatric Center
Detroit | United States
Daniel Souery
Daniel Souery
Institute of Psychiatry
United Kingdom

J Psychopharmacol 2012 May 22;26(5):603-17. Epub 2011 Sep 22.

Department of Psychiatry, General Hospital Sint-Jan Brugge-Oostende AV, Brugge, Belgium.

Depressive symptoms and episodes dominate the course of bipolar disorder. However, the therapeutic armamentarium for bipolar depression is limited. Recent evidence points to the efficacy of second generation antipsychotics (SGAs) for the treatment of bipolar depression. We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, double-blind, placebo-controlled trials; used in monotherapy) in the treatment of adult patients with bipolar depression. Publication bias was corrected for by performing similar searches using the clinical trials register of the respective pharmaceutical companies, the Cochrane Database and ClinicalTrials.gov. Seven published papers were identified on the use of aripiprazole, olanzapine and quetiapine. Internal validity of the trials was fairly good, external validity only moderate. Different outcome measures of efficacy and safety were assessed. When the individual trials were looked at, quetiapine and to a lesser extent olanzapine demonstrated significant improvement in MADRS (Montgomery-Åsberg Depression Rating Scale) total scores. This was not demonstrated for aripiprazole. Efficacy was hampered by adverse events, such as weight gain, akathisia and somnolence/sedation. Both clinical heterogeneity of the included trials and statistical heterogeneity of the meta-analytic data were considerable. The number of quetiapine trials was disproportionate to the number of trials of aripiprazole and olanzapine. Further research is needed to assess differential efficacy of the different SGAs and their use in clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269881111408461DOI Listing
May 2012
11 Reads

Publication Analysis

Top Keywords

bipolar depression
16
efficacy safety
8
review meta-analysis
8
aripiprazole olanzapine
8
treatment bipolar
8
systematic review
8
generation antipsychotics
8
second generation
8
trials
7
bipolar
5
efficacy
5
depression
5
trials looked
4
outcome measures
4
individual trials
4
assessed individual
4
looked quetiapine
4
measures efficacy
4
safety assessed
4
lesser extent
4

Similar Publications

Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.

J Clin Psychiatry 2006 Apr;67(4):509-16

Bipolar Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Background: Randomized, controlled trials have demonstrated efficacy for atypical antipsychotics in the treatment of mania in bipolar disorder, either as monotherapy or adjunctive treatment. However, there are no published comparisons of individual atypical antipsychotics for mania.

Data Sources And Study Selection: We conducted a systematic review and meta-analysis of randomized, placebo-controlled monotherapy and adjunctive therapy trials of atypical antipsychotics for acute bipolar mania. Read More

View Article
April 2006

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.

Int J Neuropsychopharmacol 2010 Feb 29;13(1):5-14. Epub 2009 Jul 29.

Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic reviews or meta-analyses to evaluate the efficacy of modern atypical antipsychotics in bipolar depression. We systematically reviewed published or registered randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I and/or II depressive patients (DSM-IV criteria). Read More

View Article
February 2010

Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.

Clin Ther 2011 Nov 4;33(11):1643-58. Epub 2011 Nov 4.

University of Florida and Florida Clinical Research Center, LLC, Maitland, Florida.

Background: Bipolar disorder, a highly recurrent and chronic condition, often necessitates periods of hospitalization and requires lifelong treatment with medication. It is characterized by alternating episodes of mania and depression. Given the severity of mania, physicians must be able to control symptoms rapidly. Read More

View Article
November 2011

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.

Arch Gen Psychiatry 2007 Apr;64(4):442-55

Department of Psychiatry and Psychotherapy, Georg-August University Goettingen, Goettingen, Germany.

Context: Recommendations of treatment guidelines concerning the use of second-generation antipsychotic (SGA) agents for acute mania vary substantially across committees or working groups. Meta-analyses addressing the use of SGAs in the treatment of acute mania are lacking.

Objective: To conduct a meta-analysis of the efficacy and safety of SGAs in the treatment of acute mania. Read More

View Article
April 2007